New Data About First-line All-oral Vinorelbine and Capecitabine in HER2-negative Metastatic Breast Cancer Confirms Results of Meta-analysis.
Professor of Medical Oncology, Tria Residence, Cankaya, Ankara, Turkey. Electronic address: altundag66@yahoo.com.
Kadri
K
Altundag
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000069287:Capecitabine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000069287:Capecitabine; D018719:Erb-b2 Receptor Tyrosine Kinases; D014747:Vinblastine; D000077235:Vinorelbine; C508053:ERBB2 protein, human